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Abstract
Background: The prevalence of diabetes mellitus (DM) continues to rise alarmingly despite years of intensive research.
The need to explore alternative remedies such as traditional phytotherapy has therefore become increasingly important
in the management and treatment of DM.
Methods: Diabetes was induced by a single intraperitoneal (i.p) injection of streptozotocin (40 mg/kg.b.w) in male
Wistar rats. The rats were divided into 5 groups as follows: non-diabetic control fed distilled water, diabetic control fed
distilled water, diabetic group treated with Tulbaghia violacea (TVL) (60 mg/kg.b.w), diabetic group treated with TVL
(120 mg/kg.b.w), and diabetic group treated with glibenclamide (10 mg/kg.b.w). Food and water intake, as well as urine
output were measured daily, whilst body weight and fasting blood glucose were monitored weekly. On day 42, an oral
glucose tolerance test was performed on all groups. After 7 weeks, the animals were sacrificed by halothane overdose,
blood was removed by cardiac puncture and tissues were harvested. Assays were performed for the determination of
plasma insulin, liver glycogen content, lipid peroxidation, antioxidant enzyme levels, plasma nitric oxide levels and serum
lipid and liver enzyme levels.
Results and Discussion: TVL treatment improved body weights, significantly reduced fasting blood glucose levels,
improved glucose tolerance and significantly increased plasma insulin and liver glycogen content. TVL treatment also
reduced liver thiobarbituric acid reactive substances (TBARS) levels, increased liver superoxide dismutase (SOD), catalase
and glutathione peroxidase (GPx) and increased plasma nitric oxide (NO) levels. Furthermore, TVL administration
reduced serum triglycerides, VLDL, total-cholesterol levels and increased HDL-cholesterol levels. TVL also reduced
serum levels of liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
Conclusion: Data obtained in this study demonstrated the hypoglycemic, antioxidant, hepatoprotective and
hypolipidemic effects of TVL in STZ-induced diabetic rats.
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Background
Diabetes mellitus (DM), one of the most challenging
health pandemics of the 21st century currently affects
about 347 million people worldwide [1]. This number is
rapidly increasing and is expected to double by the year
2030, making diabetes the 7th leading cause of death in
the world. DM is a complex metabolic disorder, character-
ized by high blood glucose levels (hyperglycaemia) and
impaired lipid, carbohydrate and protein metabolism as a
result of defects in insulin secretion, insulin action or both
[2, 3]. As a consequence of these metabolic alterations, at
least 50 % of people with diabetes develop one or more
microvascular (viz. retinopathy, neuropathy and nephrop-
athy) or macrovascular (viz. myocardial infarction, heart
failure and stroke) complications [2]. These complications
are common to both types of diabetes, despite the differ-
ence in the pathogeneses of the diseases [3].
Poor control of blood glucose levels is the key contrib-
uting factor to the associated complications and treat-
ment of hyperglycaemia is therefore, the main target in
the prevention of these diabetes- related complications
[4, 5]. Hyperglycaemia plays a critical role in the devel-
opment and progression of diabetic complications by
numerous mechanisms, including increased oxidative
stress, decreased nitric oxide bioavailability, glucose aut-
oxidation and non-enzymatic protein glycation [6]. It is
also well known that oxidative stress develops when react-
ive oxygen-derived free radical production exceeds the
antioxidant defense mechanism of the cell [6, 7]. DM has
been shown to be associated with increased free radical
formation and decreased antioxidant capacity, leading to
oxidative damage to lipid, carbohydrate, protein and nu-
cleic acids [6]. Antioxidants decrease diabetic complica-
tions by attenuation of free radical associated damage [7].
Furthermore, altered levels of blood lipids (dyslipidemia),
mainly triglyceride and cholesterol are involved in the
pathogenesis of cardiovascular disease in both type 1 and
type 2 diabetes [2, 3]. The detection and treatment of dys-
lipidemia could, therefore reduce the risk of cardiovascu-
lar disease and its consequences in diabetic patients [2].
Current therapies used in the treatment of DM include,
insulin and pharmaceutical oral hypoglycaemic/antidia-
betic agents such as sulphonylureas, biguanides and gli-
nides which have their own limitations and undesirable
side-effects such as hypoglycaemia, gastrointestinal distur-
bances, lactic acidosis and liver toxicity [8–10]. In recent
years, the search for alternative therapeutic agents in the
treatment of diabetes has been the focus of scientific re-
search. Notably in 1980 the WHO Expert Committee on
DM recommended further scientific investigations into the
therapeutic efficacy of medicinal plants due to their per-
ceived minimal side-effects. Many herbal medicines and
medicinal plants with diverse actions have been used trad-
itionally for the control, management and/or treatment of
DM in many parts of the world [3]. Consequently, screen-
ing of medicinal plants for therapeutic purposes, is im-
portant in drug development as they may possess
hypoglycaemic, hypolipidemic and antioxidant activities
which may be effective in the treatment of diabetes
mellitus [10, 11].
Tulbaghia violacea is an herbaceous plant, indigenous
to southern African countries particularly in the rocky
grasslands of the Eastern Cape, Southern KwaZulu-Natal
and Gauteng provinces of South Africa. It has been used
in folkloric medicine since early times to treat a number
of human diseases and ailments, including hypertension,
asthma, gastro-intestinal disorders, esophageal cancer,
fevers and colds, inflammation, tuberculosis and bacter-
ial infections [12–15]. It has a garlic-like odor (alliaceous
odor) that is released when the leaves or the bulbs are
bruised or damaged [16] and is commonly known as “soci-
ety garlic”, “sweet garlic” and “wild garlic” [12, 15, 17, 18].
T. violacea has been shown to have antihypertensive as
well as antioxidant effects in various rat models [19–24].
Previous studies have demonstrated the blood pressure
lowering effects of T. violacea in Dahl salt-sensitive (DSS)
rats [19, 21]. It also showed increased antioxidant activity
and decreased lipid peroxidation in rats fed T. violacea
methanolic extracts [25]. It is well known that oxidative
stress is implicated in the development of various patho-
logical conditions including hypertension and diabetes.
Hence, the present study was designed to examine the ef-
fects of T. violacea methanolic extract on blood glucose,




Streptozotocin was obtained from Sigma Aldrich (St. Louis,
MO, USA). Sandoz Glibenclamide was obtained from
Sandoz SA (Pty) Ltd. (Gauteng, South Africa). All other
chemicals used were purchased from Merck Chemicals
(Germany).
Plant material
Tulbaghia violacea rhizomes were collected in Durban,
Kwazulu Natal, identified by botanist, H. Baijnath and a
voucher specimen was deposited in the Ward herbarium
at the University of Kwazulu Natal, Durban, South Africa.
Preparation of extract
The rhizomes were washed thoroughly under tap water
and air dried at room temperature for 48 h. Thereafter,
the plant material was weighed, crushed in a Waring
blender, immersed in methanol and agitated on a shaker
for 48 h. The crude extract was then filtered using
Whatman filter paper and the filtrate was concentrated
in a rotary evaporator (Heidolph, Schwabach, Germany).
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The extract was freeze-dried and stored in a desiccator
at −4 °C for later use. The methanolic extract yield was
calculated as 1.01(g/g).
Phytochemical analysis of Tulbaghia violacea-Gas
chromatography–mass spectrometry (GC-MS)
Analysis by GC–MS was carried out using Perkin-Elmer®
Gas Chromatography (Clarus® 580) equipped with MSD
mass spectrometer (Clarus® SQ8S) instrument with built–
in autosampler. The sample was analysed on Elite-5MS
(30 m x 0.25 mm id x 0.25 μm) column. The oven
temperature was programmed from 37 to 320 °C at a rate
of 18-25 °C/min and held for 0.5 and 1.85 min at 18 and
320 °C, respectively. The injector temperature was 250 °C
and MS Ion Source temperature was 280 °C with full scan
and solvent delay of 0–2.30 min. MS Scan Range was m/z
35–500 in 0.10 s. One microlitre of the samples was
injected in Helium carrier gas at split flow of 20 ml/min.
Animals
Male Wistar rats (250–300 g) were obtained from the Bio-
medical Resource Unit (BRU) at the University of KwaZulu
Natal, Westville campus, Durban, South Africa and kept
under standard conditions (24 ± 1 °C, relative humidity
40–60 %, and 12/12 h light/dark cycle) for the 7 weeks
experimental period. The animals had free access to food
and drinking water during the entire experimental period.
The protocol used in this study was approved by the
University of KwaZulu-Natal Experimental Animal Ethics
Sub-Committee (Ethical approval number 045/13/Animal).
Induction of diabetes
Animals were fasted overnight and then injected intraperi-
toneally (i.p.) with a single dose of streptozotocin (40 mg/
kg body weight) dissolved in freshly prepared 0.1 M citrate
buffer (pH 4.5) [25]. Control rats were injected with citrate
buffer alone. Seven days following the streptozotocin in-
jection, blood was drawn from the tail vein and glucose
concentration was measured using a portable glucometer
(One Touch Select, Lifescan, Inc., CA. USA). Animals
with a fasting blood glucose concentration >25 mmol/L
were included in this study as diabetic rat.
Study design
The rats were divided into 5 groups (n = 7) as follows:
Group A : Non-diabetic control-received distilled water
(3 ml/kg.b.w).
Group B : Diabetic control- received distilled water
(3 ml/kg.b.w).
Group C : Diabetic - received TVL extract (60 mg/
kg.b.w).
Group D : Diabetic - received TVL extract (120 mg/
kg.b.w).
Group E : Diabetic - received Glibenclamide (10 mg/
kg.b.w).
TVL and glibenclamide doses were administered daily
via oral gavage. Food and water intake were monitored
daily whilst body weights were determined weekly.
Oral glucose tolerance test (OGTT)
An oral glucose tolerance test (OGTT) was performed on
each rat 6 weeks after the intervention [26]. Following a
single oral dose of glucose (2 g/kg.b.w), glucose concentra-
tions were measured in the blood collected from the tail
vein at 0 (just before glucose administration), 15, 30, 45,
60, 90, 120 and 180 min following the glucose ingestion.
Animal sacrifice
Seven weeks after treatment, the animals were sacrificed by
halothane anesthesia and blood was collected via cardiac
puncture. The heart, kidney and liver tissues of each rat
were harvested, weighed and snap frozen in liquid nitrogen.
All biological samples were stored at −70 °C until further
analysis. Sections of pancreas were removed and fixed in
buffered neutral formalin for histological preparations.
Determination of plasma insulin levels
Plasma insulin levels were measured by Enzyme-linked
Immunosorbent Assay (ELISA) technique, using an In-
sulin (Rat) Ultrasensitive ELISA kit (DRG) Diagnostics
(Marburg, Germany) [27].
Determination of liver glycogen content
The liver glycogen content was measured according to a
modified method described by Lo et al., 1970 [28].
Histopathology of the pancreas
Portions of the pancreas were excised and fixed in buffered
neutral formalin. The tissues were embedded in paraffin
wax, sectioned at 5 μ m and stained with haematoxylin
and eosin (H&E). Histological sections were examined and
scanned using a Leica SCN400 scanner (Germany) for
evaluation of morphology and morphometric analysis.
Quantitative analysis of islets was performed according to
a modified method of Masjedi et al., 2013 [29] as follows:
The number of islets in 10 microscopic fields of 10 x
100 μ m was counted and the average number of islets for
each group was calculated. Pancreatic islet size was evalu-
ated by measuring the area (μ m2) occupied by each islet
counted using the Leica SCN software and calculating the
mean area per group.
Determination of serum lipids, liver-function enzymes
Serum triglyceride, total cholesterol, HDL-cholesterol, as-
partate transaminase (AST), alanine transaminase (ALT)
and creatinine were determined using an Automated
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Chemistry Analyzer (LabmaxPlenno, Labtest, Lagoa-Santa,
Brazil) [25]. Low density lipoprotein (LDL)-cholesterol
concentrations were calculated according to the for-
mula given by Friedwald et al., 1972 [30] as follows:
LDL-cholesterol = Total cholesterol– [HDL-cholesterol +
TG/5)] where TG/5 is equivalent to the amount of very
low density lipoprotein (VLDL)-cholesterol.
Determination of lipid peroxidation in liver
Lipid peroxidation was assessed by modified method of the
thiobarbituric acid reactive substances (TBARS) assay [31].
Liver tissues (50 mg) were homogenized in 0.2 % H3PO4
(450 μ l) and centrifuged at 10000 rpm for 15 min at 4 °C.
The supernatant was decanted into glass tubes, into which
500 μ l of 2 % H3PO4 was added, and vortexed. This was
followed by the addition of 200 μ l 7 % H3PO4, TBA/BHT
(400 μ l) and1M HCl (200 μ l). The tubes were heated at
100 °C for 15 min and then allowed to cool to room
temperature. Butanol (1500 μ l) was then added to each
tube and vortexed. The top phase of each solution was
transferred in triplicate to a 96-well plate and absorbance
was measured at 532 nm and 600 nm on a Spectrostarnano
plate reader (BMG LABTECH, Ortenberg, Germany). Con-
centration was determined according to the following
formula: Concentration = [(Abs.532-Abs.600)/156]x1000.
Determination of plasma antioxidant levels
The activities of superoxide dismutase (SOD), catalase
and glutathione peroxidase (GPx) in liver samples were
determined using Biovision (California, USA) assay kits
according to the manufacturer’s instructions [32].
Determination of plasma nitric oxide levels
Plasma nitric oxide (NO) levels were measured as an in-
direct indicator of reactive nitrogen species (RNS) in
plasma. To perform this assay, 25 μ l of plasma was added
in triplicate to the wells of a 96-well microtitre plate. So-
dium nitrite (0 μM-200 μM) was used as standard in this
assay and 50 μl of its each concentration was added in
triplicate to the wells. This was followed by the rapid
addition of 50 μl vanadium chloride (VCl3), 25 μl 2 %
sulphanilamide (SULF) and 50 μl 0.1 %N-1-napthylethyle-
nediamine dihydrochloride (NEDD) into each well. The
plate was then incubated (37 °C) for 45 min under dark
conditions and the optical density was read at 540/690 nm
using a spectrophotometer (Spectrostarnano, BMG LAB-
TECH, Ortenberg Germany). A standard curve was con-
structed using the results obtained from the sodium
nitrite standard and the resultant NO concentration for
each sample was determined by extrapolation.
Statistical analysis
All data are expressed as mean ± SEM. Statistical differ-
ences between the groups were analyzed by Analysis of
Variance (ANOVA) using Graphpad prism 5.0 statistical
software, p values <0.05 were considered to be significant.
Results
GC/MS Analysis of methanolic extract of Tulbaghia
violacea
Qualitative analysis of the extract was performed using
GC-MS (Fig. 1) and the individual constituents were
identified by matching their mass spectra and retention
indices with those of inbuilt citations library. The result
of the analysis (Table 1) identified disulfides, 2, 4 -
dithiapentane, n-propyl 9, 12-octadecadienoate, methyl
5, 13-Docosadienoate, amongst others.
Food and water intake and body weight change
The average body weights, percentage left kidney weights
(%LKW), and percentage heart weights (%HW) of the
groups after 5 weeks of treatments are shown in Table 2.
The pre-treated body weights of the diabetic, TVL 60 and
TVL 120 experimental groups differed significantly from
the non-diabetic control group, p < 0.05. There were no
significant differences between the pre-treated body
weights of the various diabetic experimental groups. There
was a significant 19 % increase in the post-treated body
weights (g) of NDC compared to the pre-treated weights,
p < 0.05. D + TVL120 showed a significant 9 % increase in
body weight when post-treated weight was compared to
pre-treated body weight, p < 0.05. The post-treated body
weights of the diabetic groups were significantly reduced
compared to the non-diabetic control group, p < 0.001.
There was a significant increase in the %HW in the
diabetic control rats compared to the non-diabetic con-
trol rats, p < 0.001. The %HW did not differ significantly
when the TVL60, TVL120 and glibenclamide-treated
rats were compared to the non-diabetic group. However,
the TVL 60, TVL120 and glibenclamide treated animals
showed significant reductions in %HW compared to the
diabetic control group, p < 0.05. The %LKW increased
significantly in all diabetic rats compared to the non-
diabetic animals p < 0.001. The treated diabetic groups
showed significantly reduced % LKW weights compared to
the diabetic control group, p < 0.05. The percentage left
liver weight (%LLW) was significantly increased in the dia-
betic control, TVL 60, (p < 0.001) as well as in the TVL
120 and glibenclamide-treated groups (p < 0.01), compared
to the non-diabetic rats. The TVL 120 and glibenclamide-
treated groups showed significant reductions in % LLW
compared to the diabetic control group, p < 0.05.
The diabetic control, TVL60 and glibenclamide-treated
rats showed significantly increased food consumption
compared to the non-diabetic control group, p < 0.01.
Food consumption in the TVL120- treated group did not
differ significantly from the non-diabetic group. There
were no significant differences between the diabetic
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control group and the diabetic treated groups. Water in-
take increased significantly in the diabetic groups, com-
pared to the non-diabetic group, p < 0.001. The diabetic
rats treated with both doses of TVL and glibenclamide
showed significantly decreased water intake, compared to
the diabetic control rats, p < 0.05.
Effect of TVL on fasting blood glucose levels
The effect of TVL on mean fasting blood glucose levels is
shown in Fig. 2. Fasting blood glucose levels in the diabetic
control, diabetic + TVL60, diabetic + TVL120 and diabetic
+ glibenclamide groups were significantly increased, com-
pared to the non-diabetic group, p < 0.001. TVL (60 mg/
kg.b.w) showed a significant reduction in fasting glucose
levels at weeks 5 (35 %, p < 0.05) and 7 (40 %, p < 0.01),
respectively compared to the baseline value. TVL
(120 mg/kg.b.w) demonstrated a significant (48 %, p < 0.01)
reduction in fasting glucose at weeks 5 and 7 compared to
the baseline level. Glibenclamide treatment significantly re-
duced blood glucose levels at week 5 (28 %, p < 0.05) and
week 7 (40 %, p < 0.05).
Effect of TVL on OGTT
The effect of TVL on OGTT is shown in Fig. 3, whilst Fig. 4
represents the area under the curve (AUC). Glucose toler-
ance at 30 to 180 min was significantly improved in the
TVL (60 and 120 mg/kg.bw) treated rat groups, compared
Table 1 Compounds identified in GC-MS analysis of Tulbaghia
violacea extract
S. No Name of compound RT RI
1 Beta.-1,5-O-Dibenzoyl-ribofuranose 7.5 849
2 4-Methoxybenzaldehyde 8.1 927
3 Oleyl alcohol, trifluoroacetate 9.0 691
4 Disulfide, bis(2-sulfhydrylethyl)- 10.5 648
5 Benzene, 1-methyl-4-(methylthio)- 12.5 318
6 2, 4-Dithiapentane. 13.0 426
7 n-propyl 9,12-octadecadienoate 14.6 947
8 Methyl 5,13-Docosadienoate 14.66 690
Fig. 1 GC-MS chromatograph of methanolic extract of Tulbaghia violacea rhizomes
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to the diabetic control group (p < 0.05). The AUCglucose
value was found to be significantly increased in the un-
treated as well as in the treated diabetic groups compared
to the non-diabetic control group (p < 0.001). There were
no significant differences in the area under the curve be-
tween the diabetic groups, although there was a tendency
towards a reduction in AUCglucose in both TVL treated
groups compared to the diabetic control group after
100 min.
Effect of TVL on plasma insulin concentration
The plasma insulin levels in the various groups are shown
in Fig. 5. Plasma insulin levels wereSignificantly reduced in
the diabetic control and treated diabetic groups compared
to the non-diabetic control group (p < 0.001). TVL and
glibenclamide treatment significantly increased plasma in-
sulin compared to the diabetic control group (p < 0.05).
Effect of TVL on liver glycogen levels
The liver glycogen levels in the various groups are shown
in Fig. 6. The diabetic control group showed a significant
4-fold reduction in liver glycogen levels, compared to the
non-diabetic control group (p < 0.01). The diabetic +
TVL60, diabetic + TVL120 and diabetic + glibenclamide
groups showed significant increases in liver glycogen levels
compared to the diabetic control group (p < 0.05). There
were no significant differences in the liver glycogen levels
between the treated diabetic groups and the non-diabetic
control group.
Fig. 2 Effect of TVL on fasting blood glucose levels in non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals per
group. ***p < 0.001, significantly different compared to non-diabetic control. ap < 0.05 Significantly different from baseline value.bp < 0.05 and
bbp < 0.01, Significantly different from baseline value respectively. ccp < 0.01, Significantly different from baseline value. #p < 0.05 and ##p < 0.01,
significantly different from non-diabetic group at week 7
Table 2 Effect of TVL on pre-treated (baseline) and post-treated (week 7) bodyweights, relative organ weights and food and water
intake in rats during the experimental period
Parameters Experimental groups
NDC DC D + TVL60 D + TVL120 D + glibenclamide
Body weight (g)
Pre-treated 334.40 ± 17.82 281.30 ± 9.07* 276.00 ± 10.54* 284.10 ± 6.38* 291.50 ± 15.20
Post-treated 411.00 ± 16.27a 287.60 ± 8.88*** 295.20 ± 11.52*** 312.90 ± 8.29a*** 312.60 ± 12.71***
% HW 0.27 ± 0.022 0.35 ± 0.01*** 0.32 ± 0.01# 0.30 ± 0.01# 0.32 ± 0.01#
% LKW. 0.25 ± 0.01 0.47 ± 0.01*** 0.41 ± 0.01*** # 0.38 ± 0.02*** # 0.40 ± 0.01***#
% LLW 1.21 ± 0.09 1.75 ± 0.03*** 1.65 ± 0.03*** 1.57 ± 0.04** # 1.55 ± 0.06** #
Food intake (g/rat/day) 16.00 ± 1.47 37.00 ± 2.03** 34.75 ± 1.96** 30.00 ± 3.30* 36.67 ± 4.01**
Water intake (ml/rat/day) 18.00 ± 3.74 158.00 ± 5.83*** 132.90 ± 7.78***# 111.70 ± 11.08***# 121.70 ± 7.03***#
Non-diabetic control (NDC) and diabetic control (DC); TVL 60 mg/kg.b.w.(D + TVL 60); TVL 120 mg/kg.b.w. (D + TVL 120) and glibenclamide 10 mg/kg.b.w. (D + glibenclamide.
All data are expressed as mean ± SEM for 7 animals per group
aSignificantly different from pre-treated weight, p < 0.05
*Significantly different from NDC, p < 0.05
**Significantly different from NDC, p < 0.01
***Significantly different from NDC, p < 0.001
#Significantly different from DC, p < 0.05
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Effect of TVL on histopathology of pancreatic Islets
The histopathological changes in the pancreatic islets of
the different experimental groups are represented by Fig. 7.
Figure 7a shows the normal pancreatic islet architecture
of the non-diabetic control rat group. Degeneration and
necrosis of islets are observed in the untreated diabetic
group (Fig. 7b). The islets displayed a shrunken appearance
due to degranulation of cells. TVL 60 mg (7C) and 120 mg
(7D) as well as glibenclamide (7E) administration improved
islet morphology. Quantitative analysis of islets is shown in
Fig. 8. A significant (76 %) reduction in the number of is-
lets was found in the untreated diabetic rats, compared to
the non-diabetic control rats (p < 0.001). There were no
significant differences in islet numbers between the rats
treated with TVL and glibenclamide, compared to the
non-diabetic group. Evaluation of islet size is shown in
Fig. 9. Significant reduction in islet size was observed in
the diabetic control (85 %), compared to the non-diabetic
control group (p < 0.05). TVL and glibenclamide-treated
rats did not show significantly reduced islet numbers com-
pared to the non-diabetic control rats. However, TVL treat-
ment significantly increased the number of pancreatic
islets by about 67 %, compared to the diabetic control
group (p < 0.05). TVL120 also showed a significant 61 %
increase in islet number, compared to the glibenclamide
group. Islet size (area μ m2) was significantly increased by
71 %, 73 % and 50 % respectively, following TVL 60 mg,
TVL 120 mg and glibenclamide administration, compared
to diabetic control group (p < 0.001).
Effect of TVL on liver antioxidant enzymes, TBARS and
plasma nitric oxide levels
Oxidative stress was assessed by determining the levels of
antioxidant enzymes; superoxide dismutase (SOD), cata-
lase, and glutathione peroxidase (GPx) as well as thiobar-
bituric acid reactive substance (TBARS), a measure of
lipid peroxidation in the liver. Liver antioxidant enzyme
(SOD, GPx and catalase), liver TBARS and plasma nitric
oxide levels in the various groups are shown in Table 3.
The untreated diabetic rats showed significantly reduced
liver SOD, GPx (p < 0.01) and catalase (p < 0.05) activities
compared to the non-diabetic control group. Treatment
with 60 mg dose of TVL significantly enhanced the activity
of SOD (p < 0.05), catalase (p < 0.05) and GPx (p < 0.05).
The 120 mg dose of TVL produced significant increases
in SOD (p < 0.05), catalase (p < 0.05) and GPx (p < 0.01)
activities. Glibenclamide treatment produced significant
increases in SOD (p < 0.01); GPx (p < 0.01) and catalase
Fig. 3 Effect of TVL on OGTT in non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals per group. #Significantly
different from diabetic control, p < 0.05
Fig. 4 Area under the curve determined from OGTT graph of non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals
per group. ***Significantly different compared to non-diabetic control, p < 0.001
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activities (p < 0.05), compared to the diabetic control
group. There were no significant differences in antioxidant
activity between the treated diabetic groups compared to
the non-diabetic control group.
The diabetic control group showed a significant 51 % in-
crease in liver TBARS levels, compared to the non-diabetic
control group (p < 0.05). There were no significant differ-
ences in TBARS levels between the TVL60, TVL120 and
glibenclamide treated groups when compared to the non-
diabetic group. However, administration of TVL 60 and
120 mg/kg produced significant reductions in liver TBARS
levels, compared to the diabetic control group (p < 0.05).
Plasma nitric oxide levels decreased significantly in the
diabetic control group, compared to the non-diabetic
control group (p < 0.01). The diabetic groups treated
with TVL60mg/kg, TVL 120 mg/kg, and glibenclamide
showed significant increases in plasma NO, compared to
the diabetic control group (p < 0.05). There were no sig-
nificant differences between the treated diabetic groups
and the non-diabetic control rats.
Effect of TVL on serum lipids and liver function enzymes
Serum lipid and liver enzyme levels in the various groups
are shown in Table 4. The diabetic control group showed
a significant increase in triglyceride levels, compared to
the non-diabetic group (p < 0.05). The diabetic rats treated
with TVL 60, TVL 120 and glibenclamide showed signifi-
cant decreases in serum triglyceride levels, compared to
the diabetic control rats (p < 0.05). The triglyceride levels
of the insulin treated group did not differ significantly
from those of the diabetic control group.
Total cholesterol levels in the untreated diabetic rats
were significantly increased, compared to the non-diabetic
group (p < 0.05). The diabetic rats treated with TVL 60
and 120 mg/kg as well as glibenclamide, showed signifi-
cantly decreased total cholesterol levels compared to the
diabetic control group (p < 0.05). HDL-cholesterol levels
were significantly reduced in the diabetic rats, compared
to the non-diabetic rats (p < 0.05). Treatment with TVL
60 and 120 mg/kg significantly increased HDL-cholesterol
levels, compared to the diabetic control rats (p < 0.05).
There were no significant differences between the gliben-
clamide treated groups, compared to the diabetic control
group. The HDL-cholesterol levels of the treated dia-
betic groups did not differ significantly from the non-
diabetic group. Although there were no significant
differences (p > 0.05) in LDL-cholesterol levels between
the different experimental animal groups, the diabetic
Fig. 5 Effect of TVL on plasma insulin concentration in non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals per
group. ***Significant difference compared to non-diabetic control, p < 0.001. #Significant difference compared to diabetic control, p < 0.05
Fig. 6 Effect of TVL on liver glycogen levels in non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals per group.
**Significant difference compared to non- diabetic control, p < 0.01. #Significant difference compared to diabetic control, p < 0.05
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control group showed a tendency towards increased
LDL-cholesterol levels compared to the other groups.
The diabetic control group showed a significant in-
crease in VLDL-cholesterol levels, compared to the non-
diabetic group (p < 0.05). The diabetic rats treated with
TVL 60,TVL 120 and glibenclamide showed significantly
decreased VLDL-cholesterol levels, compared to the dia-
betic control rats(p < 0.05). The VLDL-cholesterol levels
of the treated diabetic rats did not differ significantly
from the non-diabetic control group.
Serum ALT increased significantly in the diabetic
control group, compared to the non-diabetic control
group. TVL 60 mg/kg, TVL 120 mg/kg (p < 0.01) and
glibenclamide-treated (p < 0.05) groups showed signifi-
cantly increased ALT levels, compared to the non-
diabetic group; but significantly reduced ALT levels
compared to the diabetic control group. AST levels
were significantly increased in the untreated diabetic
group, compared to the non-diabetic group whereas
TVL and glibenclamide treatments significantly re-
duced serum AST levels compared to the diabetic con-
trol group (p < 0.05).
Discussion
The present study investigated the effects of a medicinal
plant, T.violacea, on blood glucose, serum lipids and body
Fig. 7 Photomicrographs of the pancreatic islets of normal and diabetic rats. a non-diabetic control; (b); diabetic control (c) TVL 60 mg/kg.b.w.
d TVL 120 mg/kg.b.w; and (e) glibenclamide 10 mg/kg.b.w. Images taken at 20–100 μ m
Fig. 8 Effect of TVL on pancreatic islet numbers in non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals per group.
**Significantly different from non- diabetic control, p < 0.01. #Significantly different from diabetic control, p < 0.05. $Significantly different from
TVL120, p < 0.05
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antioxidant status in a streptozotocin (STZ)-induced dia-
betic rat model. STZ is widely used in experimental
animals to induce diabetes due to its toxic effect on the β-
cells of pancreatic islets, resulting in a loss of insulin
secretion [33]. STZ-induced diabetes is characterized by
hyperglycaemia, severe body weight loss, polydipsia, poly-
phagia and polyuria. In the present study, we found sig-
nificantly elevated blood glucose levels, reduced body
weights and increased water and food consumption along
with increased urine output (data not shown) in the dia-
betic rats compared to the non-diabetic rats, indicating
that diabetes was effectively induced. Treatment of dia-
betic rats with 60 and 120 mg/kg of TVL significantly
reduced water intake but did not produce significant re-
ductions in polyphagia (Table 2). Nevertheless, TVL treat-
ment significantly reduced fasting blood glucose levels
(Fig. 2) And improved glucose tolerance (Fig. 3), demon-
strating its hypoglycaemic effects in diabetic rats.
It is known that loss of body weight and decreased
growth rate in diabetic rats, despite increased food intake
is due to increased catabolism of protein as a result of in-
sulin deficiency which produces degeneration of structural
proteins and muscle wasting [1]. Treatment with TVL
(120 mg/kg) improved body weight suggesting that the
higher dose of TVL could be protective against the deg-
radation of structural proteins, possibly due to improved
glycemic control. The present study also showed increased
liver and kidney to body weight ratios in the untreated
diabetic rats. Liver hypertrophy could be attributed to
hypoinsulinaemia-induced influx of fatty acids, and de-
creased lipoprotein secretion from the liver, leading to tri-
glyceride accumulation [34]. On the other hand, TVL
treatment significantly reduced liver/body weight ratios
compared to the diabetic rats, which may be attributed to
the reduced triglyceride levels observed in the TVL-fed
groups. Our finding relating to the kidney is not surprising
since increased kidney weights in diabetes have been at-
tributed to increased protein synthesis and lipogenesis [1].
According to Eleazu et al. (2013) [1], renal hypertrophy is
considered to be early indicator of glomerular pathology
associated with diabetes.
The reduced kidney/body weight ratio observed in the
TVL-treated diabetic rats could therefore, demonstrate
potential renoprotective effects of TVL administration.
Fig. 9 Effect of TVL on Area (μ m2) of pancreatic islet in non-diabetic and diabetic rats. All data are expressed as mean ± SEM for 7 animals per
group. *Significantly different from non- diabetic control, p < 0.05. **Significantly different from non-diabetic control, p < 0.01. ***Significantly
different from non-diabetic control, p < 0.001. ###Significantly different from diabetic control, p < 0.001 $$Significantly different from
TVL120, p < 0.01
Table 3 Effect of TVL on liver antioxidant enzymes, TBARS and plasma nitric oxide levels in rats
Parameters Experimental groups
NDC DC D + TVL 60 D + TVL 120 D + glibenclamide
Liver parameters:
SOD (% Inhibition) 89.88 ± 2.71 43.82 ± 4.81** 72.71 ± 5.89# 74.08 ± 3.26# 80.56 ± 7.35##
GPx (mU/ml) 6.62 ± 0.23 1.46 ± 0.57** 4.03 ± 0.75# 6.44 ± 0.47## 6.28 ± 0.86##
Catalase (mU/ml) 0.34 ± 0.08 0.13 ± 0.02* 0.44 ± 0.05# 0.42 ± 0.08# 0.61 ± 0.07#
TBARS (nmol/mg tissue) 4.80 ± 1.65 9.86 ± 0.0.59* 7.18 ± 0.39# 5.53 ± 1.27# 7.84 ± 0.97
Plasma NO (uM) 32.61 ± 1.18 24.35 ± 0.97** 30.44 ± 1.64# 34.85 ± 3.31# 30.74 ± 3.66#
Non-diabetic control (NDC) and diabetic control (DC); TVL 60 mg/kg.b.w. TVL 120 mg/kg.b.w. (D + TVL 120) and glibenclamide 10 mg/kg.b.w. (D + glibenclamide).
All data are expressed as mean ± SEM for 7 animals per group
*Significantly different from non-diabetic control p < 0.05
**Significantly different from non-diabetic control p < 0.01
#Significantly different from diabetic control p < 0.05
##Significantly different from diabetic control p < 0.01
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Insulin deficiency or insulin resistance results in elevated
fasting and postprandial blood glucose levels [35]. How-
ever, TVL treatment produced a significant hypoglycaemic
effect by reducing fasting glucose levels (Fig. 2) and im-
proving glucose tolerance (Fig. 3). We also found signifi-
cantly increased plasma insulin levels in the TVL and
glibenclamide treated groups (Fig. 5). Histopathological
examination of the pancreatic islets showed extensive
damage to islet cells and reduction in number and size
of islets in the untreated diabetic group (Fig. 7b). TVL
(Fig. 7c and d) and glibenclamide-treatment (Fig. 7e)
improved the morphology, number and size of islet
suggesting possible protective effects of these treat-
ments against STZ-induced islet damage which may
consequently have enhanced insulin secretion as evi-
denced by increased plasma levels. Insulin is known to
stimulate glycogen synthase and inhibit glycogenolysis
in the liver, the key site for endogenous glucose produc-
tion [10, 36]. Insulin deficiency therefore, results in an
inactivation of glycogen synthase and promotes glyco-
genolysis, thereby decreasing liver glycogen content in
diabetic rats [36, 37]. Our results showed that adminis-
tration of both doses of TVL and glibenclamide signifi-
cantly increased plasma insulin and liver glycogen
levels (Fig. 5 and 6), compared to the untreated diabetic
rats, which may suggest that administration of TVL
and glibenclamide stimulated insulin secretion from
remnant pancreatic β-cells, thereby enhancing the im-
paired capacity of the liver to synthesize glycogen.
Several studies have shown that Allium sativum lowers
blood glucose in diabetic rats, and that this hypoglycaemic
effect is largely due to the sulfur-containing compounds
present in the plant [38, 39]. Some of the postulated
mechanisms underlying the hypoglycaemic action of
garlic include, increased insulin secretion from pancre-
atic β-cells or its release from bound insulin, combin-
ation with compounds such as cysteine to potentiate
serum insulin secretion, enhanced insulin sensitivity
and/or increased liver glycogen synthesis, as well as
reduced oxidative stress which ameliorates pancreatic β-cell
damage [29, 38–40]. It is likely that the organosulfur com-
pounds present in TVL have similar mechanisms of action
in effecting hypoglycaemia in diabetic rats. Treatment of
diabetic rats with the standard hypoglycaemic drug, gliben-
clamide also reduced fasting blood glucose levels, but did
not improve glucose tolerance. Glibenclamide has been
shown to exert its hypoglycaemic effect through stimulation
of insulin secretion from remnant pancreatic islet β-cells,
and inhibition of glucagon secretion [41].
In this study, we also examined the role of TVL on oxi-
dative stress in diabetes. Oxidative stress, due to increased
free radical formation and reduced antioxidant status, is
widely believed to be a key factor in the pathogenesis and
progression of diabetes [3, 39]. Available evidence strongly
suggests that excessive free radicals, particularly reactive
oxygen species (ROS) generated from hyperglycemia in-
duced glucose autoxidation and protein glycosylation, play
a critical role in diabetes [29]. STZ induces oxidative stress
and reduces antioxidant defense mechanisms in blood and
tissues, particularly the liver [29]. The hepatotoxic effect
of STZ is believed to be mediated by ROS through induc-
tion of lipid peroxidation in the hepatocellular membrane,
resulting in altered permeability and loss of membrane in-
tegrity [29]. Consistent with this, we found greatly reduced
levels of key antioxidant enzymes, SOD, CAT and GPx. as
well as elevated lipid peroxidation as evidenced by in-
creased TBARS levels in the liver of the diabetic control
rats (Table 3), an indication of STZ-induced oxidative
stress. However, TVL treatment at both 60 and 120 mg/kg
doses, produced significantly increased SOD, catalase and
GPx activity accompanied by decreased TBARS levels in
liver, demonstrating the ability of TVL to reduce oxidative
stress in diabetic rats. TVL has been shown to reduce oxi-
dative stress in a number of previously published studies
Table 4 Effect of TVL on serum lipids and liver enzymes in rats
Parameters Experimental groups
NDC DC D + TVL 60 D + TVL 120 D + glibenclamide
Triglycerides (mg/dl) 92.00 ± 10.58 134.50 ± 7.09* 100.70 ± 6.94# 93.14 ± 10.00# 93.50 ± 7.99#
Total cholesterol (mg/dl) 73.00 ± 2.48 82.25 ± 1.80 74.80 ± 5.20# 73.17 ± 4.45# 67.67 ± 4.70#
HDL-cholesterol (mg/dl) 24.40 ± 1.29 19.25 ± 0.75* 26.00 ± 1.58# 26.80 ± 1.86# 20.33 ± 2.08
LDL-cholesterol (mg/dl) 30.30 ± 1.66 36.10 ± 3.17 28.00 ± 1.88 27.67 ± 2.84 28.47 ± 3.14
VLDL (mg/dl) 18.40 ± 1.64 26.90 ± 1.42* 20.13 ± 1.39# 18.63 ± 2.00# 18.70 ± 1.60#
ALT (U/l) 62.60 ± 4.40 120.80 ± 12.52*** 78.50 ± 6.83*## 77.75 ± 3.97* ## 83.25 ± 3.82*#
AST (U/l) 76.25 ± 1.25 98.00 ± 2.30* 78.83 ± 2.32# 79.83 ± 2.46# 81.00 ± 2.58#
Non-diabetic control (NDC) and diabetic control (DC); TVL 60 mg/kg.b.w., (D + TVL 60 mg/kg.b.w.TVL 120 mg/kg.b.w.(D + TVL 120) and glibenclamide 10 mg/
kg.b.w.(D + glibenclamide). All data are expressed as mean ± SEM for 7 animals per group
*Significantly different from non-diabetic control p < 0.05
***Significantly different from non-diabetic control p < 0.001
#Significantly different from diabetic control p < 0.05
##Significantly different from diabetic control p < 0.01
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[22–24]. Moreover, garlic has been reported to exert anti-
oxidant effects by scavenging ROS and increasing SOD,
catalase and GPx. levels in cells [29]. The antioxidant ac-
tivity of garlic has been mainly attributed to the presence
of organosulfur compounds, which are believed to possess
powerful antioxidant properties and capable of stimulating
liver antioxidant enzymes [42, 43]. Our GC-MS analysis of
TVL revealed the presence of disulfides, (Table 1) which
have known antioxidant effects and could therefore con-
tribute towards the antioxidant effects of TVL.
Hyperglycaemia and hyperlipidemia, two characteristic
features of diabetes are believed to be associated with inhib-
ition of endothelial nitric oxide synthase (eNOS) and conse-
quently decreased NO production as well as increased ROS
production [44]. This may lead to endothelial dysfunction
and eventually vascular damage in the diabetic state as NO
release from the endothelium plays an important role in
regulating vascular tone [45, 46]. Notably, we also found
significantly increased plasma NO levels following TVL ad-
ministration as NO-generating compounds have been re-
ported to ameliorate hyperglycaemia and oxidative stress in
diabetic rats [47].
Abnormal lipid metabolism, leading to accumulation
of plasma LDL, VLDL and total cholesterol as well as
decreased HDL-cholesterol, is commonly associated with
DM [37]. Elevated levels of LDL, VLDL and TC are con-
sidered major risk factors for cardiovascular disease
(CVD). Conversely, increased HDL-cholesterol which
plays a key role in cholesterol transport from the periph-
ery to the liver reduces the risk of CVD [48]. The liver is
involved in the uptake and metabolism of free fatty
acids, as well as synthesis of cholesterol, triglycerides
and phospholipids [49]. Normally, triglycerides are hydro-
lyzed by the enzyme lipoprotein lipase which is activated
by insulin. However, in the diabetic state, lipoprotein lip-
ase is not activated due to insulin deficiency which results
in increased hepatic synthesis of triglycerides and an im-
balance in the release and rate of clearance of VLDL-
cholesterol by lipoprotein lipase [44]. Consistent with this,
we found elevated triglyceride, total cholesterol, VLDL-
cholesterol and decreased HDL-cholesterol levels in the
untreated diabetic rats. Treatment with TVL (60 and
120 mg/kg) produced significant reductions in serum tri-
glyceride, total cholesterol levels and VLDL-cholesterol
levels, as well as increased HDL-cholesterol levels. The re-
duced total cholesterol and increased HDL-cholesterol
levels following TVL administration are noteworthy as it
has been reported that most drugs used in the treatment
of hypercholesterolaemia reduce both total and HDL-
cholesterol levels [48]. Sulfonylurea treatment has been
found to decrease serum triglycerides and consequently,
VLDL levels due to improved glycemic control [50]. The
reductions in the serum levels of these lipids following
glibenclamide treatment support these findings. The exact
mechanisms whereby TVL exerts its hypolipidemic effects
are not known but could possibly be due to the organosul-
fur compounds present in TVL.
Elevated levels of liver transaminases, alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
are considered biomarkers of hepatocellular damage, asso-
ciated with fatty liver disease and hyperglycaemia in dia-
betes [33, 44, 51]. TVL treatment significantly reduced
ALT and AST levels, suggesting that TVL may ameliorate
STZ-induced hepatocyte injury in diabetic rats.
Conclusions
Our results show that administration of TVL methano-
lic extract produces hypoglycaemic, antioxidant and hy-
polipidemic effects in diabetic rats, thus demonstrating
its potential benefits in ameliorating some of the com-
plications associated with diabetes. Further studies are
required to identify the bioactive compounds present in
TVL as well as to elucidate the mechanisms whereby TVL
exerts its beneficial effects.
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